ACCENDRA HEALTH INC (ACH)

Sector: Health Care

    Home/Companies/ACH/Annual Meeting

2026 Annual Meeting Analysis

ACCENDRA HEALTH INC · Meeting: May 14, 2026

Policy v1.2high confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

0

Directors AGAINST

6

Say on Pay

AGAINST

Auditor

FOR

Director Elections

Election of Directors

/6 AGAINST

Against Analysis

✗ AGAINST
Mark A. Beck3-year TSR underperformance vs peer group: -88.7pp vs 20pp threshold (negative absolute TSR)director since 2019 — full tenure overlap with underperformance period5-year TSR also fails: -100.2pp vs peers well exceeds threshold

Mr. Beck has served since 2019, giving him full overlap with ACH's severe 3-year stock decline of -80.7%, which trails the company's own peer group by 88.7 percentage points — far exceeding the 20-point trigger — and the 5-year record is even worse at -100.2pp below peers, so the longer-term mitigant does not apply.

✗ AGAINST
Gwendolyn M. Bingham3-year TSR underperformance vs peer group: -88.7pp vs 20pp threshold (negative absolute TSR)director since 2020 — meaningful tenure overlap with underperformance period5-year TSR also fails: -100.2pp vs peers well exceeds threshold

Ms. Bingham has served since 2020, covering virtually the entire 3-year underperformance period in which ACH fell -80.7% while peer companies gained a median of 8.0%, a gap of 88.7 percentage points; the 5-year record shows no improvement, so no mitigant applies.

✗ AGAINST
Kenneth Gardner-Smith3-year TSR underperformance vs peer group: -88.7pp vs 20pp threshold (negative absolute TSR)director since 2022 — more than 24 months of tenure, meaningful overlap with underperformance period5-year TSR also fails

Mr. Gardner-Smith joined in 2022, placing him beyond the 24-month new-director exemption, and his tenure covers the core of the 3-year underperformance period; ACH's stock loss of -80.7% versus a peer median gain of 8.0% represents an 88.7pp gap, and the 5-year comparison at -100.2pp also triggers, so no mitigant is available.

✗ AGAINST
Stephen W. Klemash3-year TSR underperformance vs peer group: -88.7pp vs 20pp threshold (negative absolute TSR)director since 2021 — meaningful tenure overlap with underperformance period5-year TSR also fails

Mr. Klemash has served since 2021, giving him substantial overlap with the 3-year period in which ACH lost -80.7% while peers gained 8.0% on median — an 88.7pp gap that far exceeds the 20pp trigger — and the 5-year comparison confirms the underperformance is sustained, not a recent blip.

✗ AGAINST
Teresa L. Kline3-year TSR underperformance vs peer group: -88.7pp vs 20pp threshold (negative absolute TSR)director since 2022 — more than 24 months of tenure, meaningful overlap with underperformance period5-year TSR also fails

Ms. Kline joined in 2022 and is beyond the new-director exemption; her tenure coincides with the bulk of ACH's -80.7% stock decline versus a peer median gain of 8.0%, a gap of 88.7pp, and the 5-year comparison at -100.2pp below peers also triggers, eliminating any longer-track-record mitigant.

✗ AGAINST
Edward A. Pesicka3-year TSR underperformance vs peer group: -88.7pp vs 20pp threshold (negative absolute TSR)director and CEO since 2019 — full tenure overlap with underperformance period5-year TSR also fails: -100.2pp vs peersexecutive director subject to same TSR trigger as all other directors, independent of Say on Pay vote

As both CEO and director since 2019, Mr. Pesicka bears the most direct accountability for ACH's catastrophic stock performance — a -80.7% three-year decline versus a peer median gain of 8.0% (a gap of 88.7pp) — and the 5-year picture is worse at -100.2pp below peers, so no mitigant applies; this AGAINST vote on his director seat is independent of the separate Say on Pay analysis.

For Analysis

All six director nominees trigger the TSR underperformance policy. ACH's 3-year stock return of -80.7% trails the company's own disclosed compensation peer group median of +8.0% by 88.7 percentage points, far exceeding the 20pp threshold that applies when absolute returns are negative. The 5-year comparison (-100.2pp below peers) confirms that underperformance is sustained, eliminating the longer-track-record mitigant for all directors. No director benefits from the new-director (under 24 months) exemption. The policy requires an AGAINST vote on each director individually.

Say on Pay

✗ AGAINST

CEO

Edward A. Pesicka

Total Comp

$11,157,809

Prior Support

95%%

CEO total compensation $11.16M likely above benchmark for $201M market cap healthcare companypay-for-performance misalignment: CEO paid $345K bonus despite 0% corporate performance achievement on all metrics; $9.56M in equity granted while stock down 71% in one year3-year TSR trails peers by 88.7pp while above-benchmark equity grants continue

ACH's stock has lost 80.7% over three years while peers gained a median of 8.0%, yet the CEO received total compensation of $11.16 million in 2025 — a level calibrated to a far larger company than the current $201 million market cap. The pay-for-performance alignment check fails: the company missed every single one of its 2025 financial targets at 0% achievement (EBITDA, revenue, and net debt reduction all came in below threshold), yet the CEO was still awarded $345,000 in bonus pay plus $9.56 million in equity grants. While the company's rationale for a modest 20% bonus payout — recognizing the CEO's role in the P&HS divestiture — has some merit, the overall compensation package is not aligned with the experience of shareholders who have seen their investment lose roughly 93% of its value over five years, making a FOR vote inappropriate.

Auditor Ratification

✓ FOR

Auditor

KPMG LLP

Tenure

N/A

Audit Fees

$5,402,360

Non-Audit Fees

$758,628

non-audit fee ratio: ~14% of audit fees — well within 50% thresholdtenure not disclosed — no tenure trigger fired; noted as minor negativeKPMG is a Big 4 firm appropriate for ACH's size

Non-audit fees (audit-related fees of $555,000 plus tax fees of $49,728 plus other fees of $153,900, totaling approximately $758,628) represent roughly 14% of audit fees of $5,402,360 — comfortably below the 50% threshold that would raise independence concerns. KPMG is a Big 4 firm that is fully appropriate for a company of ACH's size and complexity. Auditor tenure is not disclosed in the proxy, so the tenure trigger cannot fire; this is noted as a minor negative but does not change the vote.

Overall Assessment

This ballot presents significant governance concerns at Accendra Health: the stock has lost over 80% in three years while trailing its own peer group by nearly 90 percentage points, triggering AGAINST votes on all six director nominees and the Say on Pay proposal. The auditor ratification passes cleanly on fee ratios, and the equity plan approval falls outside current policy coverage.

Filing date: April 2, 2026·Policy v1.2·high confidence

Compensation Peer Group

14 companies disclosed in 2026 proxy filing

AHCOAdaptHealth Corp.
BAXBaxter International Inc.
BSXBoston Scientific Corporation
CHRWC.H. Robinson Worldwide, Inc.
XRAYDENTSPLY SIRONA Inc.
HSICHenry Schein, Inc.
HOLXHologic, Inc.
PDCOPatterson Companies, Inc.
DGXQuest Diagnostics Incorporated
RMDResMed Inc.
SEMSelect Medical Holdings Corporation
STESTERIS plc
WCCWESCO International, Inc.
ZBHZimmer Biomet Holdings, Inc.